= Solution
\b[Mouse models allow causal and longitudinal tests in an intact organism, but their value depends on which part of human <cancer> the chosen model reproduces.] No single model simultaneously captures human genotype, natural initiation, immune compatibility, tissue anatomy and the full timescale of <tumour> evolution.
A major strength is experimental control. Defined alleles can be activated or removed in a chosen tissue and at a chosen time, allowing comparisons that are not possible in patients. Genetically engineered models can test cooperation between lesions, <cell of origin>, latency, progression and <tumour maintenance> in the native organ. Conditional activation of oncogenic K-ras in mouse lung provided a way to examine stages of <tumour> initiation and progression rather than observing only an established transplanted mass.<Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras by Erica L. Jackson and others>[Conditional activation and staged lung pathology]{ref} A reversible or inducible intervention after <tumour> formation can then distinguish an initiation requirement from a maintenance dependency. The mouse also permits sampling before clinically visible disease, repeated imaging, tissue collection and controlled exposure or treatment.
The host environment is another advantage. <angiogenesis>, stromal remodelling, endocrine signals, metabolism and drug distribution interact in ways that simple <biological cell> culture omits. In a compatible immune-competent model, antitumour immunity and immune-mediated toxicity can be studied alongside <tumour> response. Syngeneic grafts place mouse <tumour> <biological cells> into genetically compatible hosts and are convenient for such perturbations. Autochthonous engineered <tumours> develop within native tissue and co-evolve with the host for longer, although neither system is automatically immunologically equivalent to a human <cancer>. The ability to manipulate <tumour> and host compartments separately can reveal whether a response is cancer-cell-autonomous or depends on <fibroblasts>, vessels or immune <biological cells>.
Human <xenografts> provide a different advantage. Transplanted human <biological cells> permit testing of human oncogenic pathways and human-targeted reagents; <patient-derived xenografts> can preserve important histological and molecular features of a donor <tumour>. Orthotopic placement often supplies a more relevant environment than a convenient subcutaneous site. Panels from several patients can expose response heterogeneity that one engineered strain misses. Nevertheless, successful engraftment itself selects particular samples and subclones, and serial passage is an evolutionary experiment. Ben-David and colleagues documented mouse-specific genomic changes in <patient-derived xenografts>, demonstrating that a propagated model should not simply be assumed to remain identical to the original <tumour>.<Patient-derived xenografts undergo mouse-specific tumor evolution by Uri Ben-David and others>[Longitudinal copy-number changes during xenograft propagation]{ref} Compare early and late passages with the donor, and use the passage appropriate to the question.
The greatest <xenograft> limitation for many questions is the host. Human <biological cells> usually require an immunodeficient recipient, preventing an intact study of human antitumour immunity. Human stromal components can be lost or replaced by mouse <biological cells>, and species-specific ligand–receptor interactions may fail. Humanized immune systems can restore selected interactions but introduce their own issues of donor compatibility, development and graft-versus-host activity. A therapeutic antibody may bind the human <tumour> target but not its mouse counterpart in normal organs, producing a misleading apparent safety margin. Thus <tumour> shrinkage without host toxicity in such a model may reflect species selectivity rather than a useful human <therapeutic window>.
Engineered and syngeneic models also have limitations. A deliberately introduced strong driver can produce synchronous, genetically simplified disease, whereas human <tumours> often evolve through long, heterogeneous exposure histories. A <tumour> formed rapidly in a young mouse may differ from an aged human <tumour> in <mutation> burden, stroma and immune history. <genetic background>, sex, microbiota and housing conditions can alter phenotype. Species differences in lifespan, organ structure, metabolism, telomere regulation and drug <pharmacokinetics> further limit direct extrapolation. The <tumour> spectrum after <p53> loss, for example, is informative about <tumour> suppression but does not by itself reproduce the distribution of human TP53-mutant <cancers>.<Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours by L. A. Donehower and others>[Spontaneous-tumour model and its tissue context]{ref}
The endpoint and intervention must fit the biological question. Subcutaneous growth measures a local mass under an artificial geometry; tail-vein injection measures selected post-entry metastatic steps. Neither establishes a treatment effect on natural invasion or initial dissemination. Drug tests should establish exposure and <target engagement> in both <tumour> and relevant normal tissue, use clinically motivated schedules where possible, and measure survival or durable disease control as well as short-term volume. Rapidly growing implants may make some treatments look more effective than they are against slow, heterogeneous human disease.
Good design uses random allocation after a defined eligibility point, blinded measurement, prespecified endpoints and justified numbers of independent animals. Multiple <tumours> within one mouse are not automatically independent treatment replicates. Match or record relevant background variables and validate the intended allelic change and molecular phenotype. Ethical constraints favour well-chosen questions and informative longitudinal measurements rather than duplicating a weak model at larger scale. Combine mouse results with human genomics, patient-derived cultures or <organoids> and, ultimately, human evidence. \b[A mouse experiment is strongest when it tests a defined causal mechanism and its known limits; concordance across complementary models is more persuasive than a claim that one mouse <cancer> represents human <cancer> in general.]
Back to article page
